|
1
|
Yao JC, Hassan M, Phan A, Dagohoy C, Leary
C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A and Evans
DB: One hundred years after ‘carcinoid’: Epidemiology of and
prognostic factors for neuroendocrine tumors in 35,825 cases in the
United States. J Clin Oncol. 26:3063–3072. 2008.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Tsai HJ, Wu CC, Tsai CR, Lin SF, Chen LT
and Chang JS: The epidemiology of neuroendocrine tumors in Taiwan:
A nation-wide cancer registry-based study. PLoS One.
8(e62487)2013.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Catena L, Bichisao E, Milione M, Valente
M, Platania M, Pusceddu S, Ducceschi M, Zilembo N, Formisano B and
Bajetta E: Neuroendocrine tumors of unknown primary site: Gold dust
or misdiagnosed neoplasms? Tumori. 97:564–567. 2011.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Scoazec JY, Couvelard A, Monges G,
Guyétant S, Bisot-Locard S, Parot X and Lepage C: PRONET Study
Group. Professional practices and diagnostic issues in
neuroendocrine tumour pathology: Results of a prospective one-year
survey among French pathologists (the PRONET study).
Neuroendocrinology. 105:67–76. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Hankus J and Tomaszewska R: Neuroendocrine
neoplasms and somatostatin receptor subtypes expression. Nucl Med
Rev Cent East Eur. 19:111–117. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Hope TA, Bergsland EK, Bozkurt MF, Graham
M, Heaney AP, Herrmann K, Howe JR, Kulke MH, Kunz PL, Mailman J, et
al: Appropriate use criteria for somatostatin receptor PET imaging
in neuroendocrine tumors. J Nucl Med. 59:66–74. 2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Bellizzi AM: Assigning site of origin in
metastatic neuroendocrine neoplasms: A clinically significant
application of diagnostic immunohistochemistry. Adv Anat Pathol.
20:285–314. 2013.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Maxwell JE, Sherman SK, Stashek KM,
O'Dorisio TM, Bellizzi AM and Howe JR: A practical method to
determine the site of unknown primary in metastatic neuroendocrine
tumors. Surgery. 156:1359–1366. 2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Kerr SE, Schnabel CA, Sullivan PS, Zhang
Y, Huang VJ, Erlander MG, Brachtel EF and Dry SM: A 92-gene cancer
classifier predicts the site of origin for neuroendocrine tumors.
Mod Pathol. 27:44–54. 2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Hainsworth JD, Spigel DR, Litchy S and
Greco FA: Phase II trial of paclitaxel, carboplatin, and etoposide
in advanced poorly differentiated neuroendocrine carcinoma: A
minnie pearl cancer research network study. J Clin Oncol.
24:3548–3554. 2006.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Spigel DR, Hainsworth JD and Greco FA:
Neuroendocrine carcinoma of unknown primary site. Semin Oncol.
36:52–59. 2009.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Pavel M, Baudin E, Couvelard A, Krenning
E, Öberg K, Steinmüller T, Anlauf M, Wiedenmann B and Salazar R:
Barcelona consensus conference participants. ENETS consensus
guidelines for the management of patients with liver and other
distant metastases from neuroendocrine neoplasms of foregut,
midgut, hindgut, and unknown primary. Neuroendocrinology.
95:157–176. 2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Sadowski SM, Neychev V, Millo C, Shih J,
Nilubol N, Herscovitch P, Pacak K, Marx SJ and Kebebew E:
Prospective study of 68Ga-DOTATATE positron emission
tomography/computed tomography for detecting
gastro-entero-pancreatic neuroendocrine tumors and unknown primary
sites. J Clin Oncol. 34:588–596. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Crown A, Rocha FG, Raghu P, Lin B, Funk G,
Alseidi A, Hubka M, Rosales J, Lee M and Kennecke H: Impact of
initial imaging with gallium-68 dotatate PET/CT on diagnosis and
management of patients with neuroendocrine tumors. J Surg Oncol.
121:480–485. 2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Glazer ES, Tseng JF, Al-Refaie W,
Solorzano CC, Liu P, Willborn KA, Abdalla EK, Vauthey JN and Curley
SA: Long-term survival after surgical management of neuroendocrine
hepatic metastases. HPB (Oxford). 12:427–433. 2010.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Lesurtel M, Nagorney DM, Mazzaferro V,
Jensen RT and Poston GJ: When should a liver resection be performed
in patients with liver metastases from neuroendocrine tumours? A
systematic review with practice recommendations. HPB (Oxford).
17:17–22. 2015.PubMed/NCBI View Article : Google Scholar
|
